Transmedics Group Inc (TMDX)
$87.11
+6.5
(+8.06%)▲
Transmedics Group Inc Key Statistics
Market Capitalization | $2.9B |
Revenue TTM | $401.1M |
EBITDA | $51.1M |
Earnings Per Share (EPS) | $1.0 |
PE Ratio | 87.11 |
Profit Margin | 8.14% |
Quarterly Earnings Growth YOY | 0.0% |
Return On Equity TTM | 19.41% |
Transmedics Group Inc share price movements
- $82.15$87.84$87.11
5.7%
Downside
Day's Volatility :6.48%
Upside
0.83%
- $68.84$177.37$87.11
20.97%
Downside
52 Weeks Volatility :61.19%
Upside
50.89%
Transmedics Group Inc Returns
| Period | Transmedics Group Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -47.73% | -5.9% | 0.0% |
6 Months | -38.78% | 3.8% | 0.0% |
1 Year | 19.57% | 13.3% | 0.0% |
3 Years | 299.59% | 11.0% | -21.1% |
Analyst Recommendation on Transmedics Group Inc
- Current
- 1M Ago
- 3M Ago
Analyst Forecast on Transmedics Group Inc
What analysts predicted
Upside of 42.21%
Insights on Transmedics Group Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 114.30M → 108.76M (in $), with an average decrease of 4.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 12.19M → 4.21M (in $), with an average decrease of 32.7% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 63.7% return, outperforming this stock by 44.1%
Transmedics Group Inc Technicals Summary
Sell
Neutral
Buy
Transmedics Group Inc is currently in a neutral trading position according to technical analysis indicators.
Transmedics Group Inc Vs Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Transmedics Group Inc | -1.57% | -38.78% | 19.57% | 299.59% | 364.59% |
 Stryker Corporation | 8.11% | 13.78% | 31.85% | 59.4% | 89.47% |
 Boston Scientific Corp. | 7.32% | 21.03% | 63.69% | 135.16% | 109.83% |
 Edwards Lifesciences Corp. | 3.89% | -17.19% | 6.88% | -34.9% | -11.73% |
 Abbott Laboratories | 4.89% | 18.09% | 14.78% | -7.09% | 39.2% |
 Medtronic Plc | -4.48% | 5.87% | 9.4% | -21.77% | -22.55% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Transmedics Group Inc | 87.11 | 87.11 | NA | 0.97 | 0.19 | 0.03 | NA | 6.26 |
Stryker Corporation | 41.65 | 41.65 | 2.72 | 12.06 | 0.19 | 0.07 | 0.01 | 52.86 |
Boston Scientific Corp. | 74.39 | 74.39 | 1.64 | 2.46 | 0.09 | 0.05 | NA | 14.05 |
Edwards Lifesciences Corp. | 27.83 | 27.83 | 6.56 | 2.53 | 0.19 | 0.11 | NA | 16.18 |
Abbott Laboratories | 36.16 | 36.16 | 2.29 | 4.68 | 0.15 | 0.06 | 0.02 | 22.94 |
Medtronic Plc | 26.38 | 26.38 | 1.56 | 5.2 | 0.08 | 0.04 | 0.03 | 38.29 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Transmedics Group Inc | Buy | $2.9B | 364.59% | 87.11 | 8.14% |
Stryker Corporation | Buy | $148.0B | 89.47% | 41.65 | 16.34% |
Boston Scientific Corp. | Buy | $133.8B | 109.83% | 74.39 | 11.26% |
Edwards Lifesciences Corp. | Buy | $42.5B | -11.73% | 27.83 | 65.86% |
Abbott Laboratories | Buy | $206.3B | 39.2% | 36.16 | 13.99% |
Medtronic Plc | Buy | $110.6B | -22.55% | 26.38 | 12.06% |
Transmedics Group Inc Institutional Holdings
Vanguard Group Inc
10.71%BlackRock Inc
7.88%FMR Inc
6.35%Driehaus Capital Management LLC
4.43%Amvescap Plc.
4.06%Morgan Stanley - Brokerage Accounts
3.05%
About Transmedics Group Inc
transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Organization | Transmedics Group Inc |
Employees | 584 |
CEO | Mr. Nicholas Corcoran |
Industry | Medical Specialties |
